|
Acadia Pharmaceuticals Inc. (Acad) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
ACADIA Pharmaceuticals Inc. (ACAD) Bundle
Unser Acad DCF-Taschenrechner wurde für die Genauigkeit entwickelt und ermöglicht es Ihnen, Acadia Pharmaceuticals Inc. (ACAD) -Schange mithilfe realer Finanzdaten zu bewerten und bietet vollständige Flexibilität, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 441.8 | 484.1 | 517.2 | 726.4 | 957.8 | 1,170.2 | 1,429.8 | 1,747.0 | 2,134.5 | 2,607.9 |
| Revenue Growth, % | 0 | 9.6 | 6.83 | 40.45 | 31.85 | 22.18 | 22.18 | 22.18 | 22.18 | 22.18 |
| EBITDA | -286.6 | -167.1 | -221.6 | -67.8 | 100.2 | -330.3 | -403.5 | -493.0 | -602.4 | -736.0 |
| EBITDA, % | -64.87 | -34.51 | -42.84 | -9.34 | 10.46 | -28.22 | -28.22 | -28.22 | -28.22 | -28.22 |
| Depreciation | 2.9 | 3.3 | 2.0 | 5.6 | 15.9 | 9.8 | 11.9 | 14.6 | 17.8 | 21.7 |
| Depreciation, % | 0.66372 | 0.6907 | 0.3917 | 0.76428 | 1.66 | 0.83374 | 0.83374 | 0.83374 | 0.83374 | 0.83374 |
| EBIT | -289.5 | -170.4 | -223.6 | -73.4 | 84.3 | -340.0 | -415.4 | -507.6 | -620.2 | -757.7 |
| EBIT, % | -65.54 | -35.2 | -43.23 | -10.1 | 8.8 | -29.05 | -29.05 | -29.05 | -29.05 | -29.05 |
| Total Cash | 632.0 | 520.7 | 416.8 | 438.9 | 756.0 | 982.8 | 1,200.9 | 1,467.2 | 1,792.7 | 2,190.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 50.3 | 65.3 | 63.1 | 102.4 | 98.7 | 143.9 | 175.8 | 214.8 | 262.4 | 320.6 |
| Account Receivables, % | 11.38 | 13.5 | 12.2 | 14.09 | 10.31 | 12.29 | 12.29 | 12.29 | 12.29 | 12.29 |
| Inventories | 9.7 | 7.9 | 6.6 | 35.8 | 21.9 | 28.8 | 35.2 | 43.1 | 52.6 | 64.3 |
| Inventories, % | 2.19 | 1.63 | 1.28 | 4.93 | 2.29 | 2.46 | 2.46 | 2.46 | 2.46 | 2.46 |
| Accounts Payable | 8.5 | 6.9 | 12.7 | 17.5 | 16.2 | 23.2 | 28.3 | 34.6 | 42.3 | 51.7 |
| Accounts Payable, % | 1.92 | 1.42 | 2.46 | 2.41 | 1.69 | 1.98 | 1.98 | 1.98 | 1.98 | 1.98 |
| Capital Expenditure | -7.6 | -1.1 | .0 | -40.1 | -.5 | -17.6 | -21.5 | -26.3 | -32.1 | -39.2 |
| Capital Expenditure, % | -1.72 | -0.23175 | 0 | -5.51 | -0.05460447 | -1.5 | -1.5 | -1.5 | -1.5 | -1.5 |
| Tax Rate, % | 12.25 | 12.25 | 12.25 | 12.25 | 12.25 | 12.25 | 12.25 | 12.25 | 12.25 | 12.25 |
| EBITAT | -290.1 | -170.8 | -226.2 | -88.1 | 74.0 | -331.7 | -405.2 | -495.1 | -605.0 | -739.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -346.3 | -183.5 | -214.8 | -186.3 | 105.4 | -384.5 | -448.0 | -547.4 | -668.8 | -817.1 |
| WACC, % | 5.75 | 5.75 | 5.75 | 5.75 | 5.74 | 5.75 | 5.75 | 5.75 | 5.75 | 5.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,379.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -833 | |||||||||
| Terminal Value | -22,241 | |||||||||
| Present Terminal Value | -16,819 | |||||||||
| Enterprise Value | -19,199 | |||||||||
| Net Debt | -268 | |||||||||
| Equity Value | -18,931 | |||||||||
| Diluted Shares Outstanding, MM | 166 | |||||||||
| Equity Value Per Share | -113.80 |
What You Will Get
- Real ACAD Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on ACADIA Pharmaceuticals' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue projections, R&D expenses, and operating margins.
- Instant DCF Valuation: Quickly determines intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Incorporates ACADIA’s actual financial data for credible valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Streamline the valuation process without the hassle of constructing intricate models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based ACAD DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other key metrics.
- Instant Calculations: The model automatically recalculates ACAD's intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial strategies.
Why Choose ACADIA Pharmaceuticals Inc. (ACAD) Calculator?
- Comprehensive Tool: Incorporates DCF, WACC, and financial ratio analyses tailored for ACAD.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for ACAD.
- Detailed Insights: Automatically computes ACAD’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on ACAD.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling ACADIA Pharmaceuticals Inc. (ACAD) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for ACADIA Pharmaceuticals Inc. (ACAD).
- Consultants: Deliver professional valuation insights on ACADIA Pharmaceuticals Inc. (ACAD) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like ACADIA Pharmaceuticals Inc. (ACAD) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to ACADIA Pharmaceuticals Inc. (ACAD).
What the Template Contains
- Pre-Filled DCF Model: ACADIA Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate ACADIA’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.